Skip Navigation

Text From Here.

Seiko Hirono(M.D.,Ph.D.)

  • Assistant Professor
  • Clinic day:
  • Area of Practice: Hepato-biliary-pancreatic surgery

EDUCATION

  • 2009 Ph.D.    Wakayama Medical University, School of Medicine, Japan
  • 2000 M.D. Wakayama Medical University ,School of Medicine, Wakayama, Japan

PROFESSIONAL EXPERIENCE AND EMPLOYMENT

  • April, 2000-March, 2002

Clinical Trainee, Second Dept. of Surgery, Wakayama Medical University

  • April, 2002-March, 2004

Medical staff, Surgery Dept, Naga Public Hospital

  • April, 2004-March, 2008

Graduate student, Second Dept. of Surgery, Wakayama Medical University

(Basic research in Cancer Institute from April, 2005 to September, 2007)

  • April, 2008-December, 2012

Surgical staff, Second Dept. of Surgery, Wakayama Medical University

  • January, 2013-August, 2014

Assistant Professor, Second Dept. of Surgery, Wakayama Medical University

  • September, 2014-present

Associate Professor, Second Dept. of Surgery, Wakayama Medical University

BOARD CERTIFICATION

  • Councilor, Board Certified Surgeon, Board Certified Instructor, The Japanese Society of Gastroenterological Surgery
  • Board Certified Surgeon, Board Certified Instructor, The Japan Surgical Society
  • Councilor, Board Certified Expert Surgeon, The Japanese Society of Hepato-Biliary-Pancreatic Surgery
  • Board Certified Gastroenterologist, The Japanese Society of Gastroenterology
  • General Clinical Oncologist, Japanese Board of Cancer Therapy

RESEARCH

Clinical research; I have been handling 2 prospective studies: 1) randomized clinical trial: horizontal mattress vs. interrupted suture in surgical techniques of pancreaticojejunostomy (NCT01898780), and 2) Prospective observational study (Japan-Taiwan cooperative project): predictive risk factors for pancreatic fistula grade C after pancreaticoduodenectomy (NCT02322424).

Basic research; I have been handling 2 studies: 1) identification of significant biomarkers to distinguish between malignant and benign intraductal papillary mucinous neoplasms, and 2) development of novel therapy using peptide vaccine derived from MUC16 and mesothelin for pancreatic cancer.